
Patient Preference and Adherence, Journal Year: 2024, Volume and Issue: Volume 18, P. 2261 - 2280
Published: Nov. 1, 2024
Clozapine is an antipsychotic which was approved in 1989 for treatment-resistant schizophrenia the United States (US). There were few randomized trials before its approval and potentially lethal clozapine adverse drug reactions (ADRs), such as agranulocytosis myocarditis identified by pharmacovigilance. VigiBase, WHO global database, a cornerstone of international pharmacovigilance efforts ADR identification during post-marketing surveillance. This systematic review literature explores additional contributions to knowledge ADRs from recent VigiBase studies.
Language: Английский